Cargando…

Analytical Evaluation of the New Beckman Coulter Access Procalcitonin (PCT) Chemiluminescent Immunoassay

This study was designed to evaluate the analytical performance of the recently commercialized Beckman Coulter Access procalcitonin (PCT) chemiluminescent test on the Access immunoassay system. The analytical assessment encompassed the estimation of limit of blank (LoB), limit of detection (LoD), fun...

Descripción completa

Detalles Bibliográficos
Autores principales: Lippi, Giuseppe, Salvagno, Gian Luca, Gelati, Matteo, Pucci, Mairi, Demonte, Davide, Faggian, Diego, Plebani, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151122/
https://www.ncbi.nlm.nih.gov/pubmed/32111028
http://dx.doi.org/10.3390/diagnostics10030128
_version_ 1783521177396838400
author Lippi, Giuseppe
Salvagno, Gian Luca
Gelati, Matteo
Pucci, Mairi
Demonte, Davide
Faggian, Diego
Plebani, Mario
author_facet Lippi, Giuseppe
Salvagno, Gian Luca
Gelati, Matteo
Pucci, Mairi
Demonte, Davide
Faggian, Diego
Plebani, Mario
author_sort Lippi, Giuseppe
collection PubMed
description This study was designed to evaluate the analytical performance of the recently commercialized Beckman Coulter Access procalcitonin (PCT) chemiluminescent test on the Access immunoassay system. The analytical assessment encompassed the estimation of limit of blank (LoB), limit of detection (LoD), functional sensitivity (i.e., PCT value with ≤10% imprecision), linearity, imprecision and comparability of values with BRAHMS PCT-sensitive Kryptor. LoB, LoD and functional sensitivity were 0.002 μg/L, 0.003 μg/L and 0.003 μg/L, respectively. Intra-assay, inter-assay and total imprecision for plasma pools with low, medium and high PCT values were 1.8–2.1%, 2.4–3.7% and 3.1–4.3%, respectively. The assay exhibited excellent linearity between 0.02 and 84.0 μg/L. Excellent correlation (r = 0.999; p < 0.001) and negligible bias (3.2%) were found by comparing values obtained in paired plasma samples with BRAHMS PCT-sensitive Kryptor. Diagnostic agreement at 0.5, 2.0 and 10 μg/L PCT values ranged between 98%-100%. The results of this study confirm that Access PCT displays excellent analytical performance and high comparability with BRAHMS PCT-sensitive Kryptor.
format Online
Article
Text
id pubmed-7151122
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71511222020-04-20 Analytical Evaluation of the New Beckman Coulter Access Procalcitonin (PCT) Chemiluminescent Immunoassay Lippi, Giuseppe Salvagno, Gian Luca Gelati, Matteo Pucci, Mairi Demonte, Davide Faggian, Diego Plebani, Mario Diagnostics (Basel) Communication This study was designed to evaluate the analytical performance of the recently commercialized Beckman Coulter Access procalcitonin (PCT) chemiluminescent test on the Access immunoassay system. The analytical assessment encompassed the estimation of limit of blank (LoB), limit of detection (LoD), functional sensitivity (i.e., PCT value with ≤10% imprecision), linearity, imprecision and comparability of values with BRAHMS PCT-sensitive Kryptor. LoB, LoD and functional sensitivity were 0.002 μg/L, 0.003 μg/L and 0.003 μg/L, respectively. Intra-assay, inter-assay and total imprecision for plasma pools with low, medium and high PCT values were 1.8–2.1%, 2.4–3.7% and 3.1–4.3%, respectively. The assay exhibited excellent linearity between 0.02 and 84.0 μg/L. Excellent correlation (r = 0.999; p < 0.001) and negligible bias (3.2%) were found by comparing values obtained in paired plasma samples with BRAHMS PCT-sensitive Kryptor. Diagnostic agreement at 0.5, 2.0 and 10 μg/L PCT values ranged between 98%-100%. The results of this study confirm that Access PCT displays excellent analytical performance and high comparability with BRAHMS PCT-sensitive Kryptor. MDPI 2020-02-26 /pmc/articles/PMC7151122/ /pubmed/32111028 http://dx.doi.org/10.3390/diagnostics10030128 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Lippi, Giuseppe
Salvagno, Gian Luca
Gelati, Matteo
Pucci, Mairi
Demonte, Davide
Faggian, Diego
Plebani, Mario
Analytical Evaluation of the New Beckman Coulter Access Procalcitonin (PCT) Chemiluminescent Immunoassay
title Analytical Evaluation of the New Beckman Coulter Access Procalcitonin (PCT) Chemiluminescent Immunoassay
title_full Analytical Evaluation of the New Beckman Coulter Access Procalcitonin (PCT) Chemiluminescent Immunoassay
title_fullStr Analytical Evaluation of the New Beckman Coulter Access Procalcitonin (PCT) Chemiluminescent Immunoassay
title_full_unstemmed Analytical Evaluation of the New Beckman Coulter Access Procalcitonin (PCT) Chemiluminescent Immunoassay
title_short Analytical Evaluation of the New Beckman Coulter Access Procalcitonin (PCT) Chemiluminescent Immunoassay
title_sort analytical evaluation of the new beckman coulter access procalcitonin (pct) chemiluminescent immunoassay
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151122/
https://www.ncbi.nlm.nih.gov/pubmed/32111028
http://dx.doi.org/10.3390/diagnostics10030128
work_keys_str_mv AT lippigiuseppe analyticalevaluationofthenewbeckmancoulteraccessprocalcitoninpctchemiluminescentimmunoassay
AT salvagnogianluca analyticalevaluationofthenewbeckmancoulteraccessprocalcitoninpctchemiluminescentimmunoassay
AT gelatimatteo analyticalevaluationofthenewbeckmancoulteraccessprocalcitoninpctchemiluminescentimmunoassay
AT puccimairi analyticalevaluationofthenewbeckmancoulteraccessprocalcitoninpctchemiluminescentimmunoassay
AT demontedavide analyticalevaluationofthenewbeckmancoulteraccessprocalcitoninpctchemiluminescentimmunoassay
AT faggiandiego analyticalevaluationofthenewbeckmancoulteraccessprocalcitoninpctchemiluminescentimmunoassay
AT plebanimario analyticalevaluationofthenewbeckmancoulteraccessprocalcitoninpctchemiluminescentimmunoassay